BACKGROUND: TOMM40 (translocase of the outer mitochondrial membrane pore subunit) is in linkage disequilibrium with apolipoprotein E (APOE). APOE e4 is linked to long (L; 21-29 T residues) poly-T variants within intron 6 of TOMM40, whereas APOE e3 can be associated with either a short (S; <21 T residues) or very long (VL; >29 T residues) variant. To assess the possible contribution of TOMM40 to Alzheimer's disease onset, we compared the effects of TOMM40 and APOE genotype on preclinical longitudinal memory decline. METHODS: An APOE e4-enriched cohort of 639 cognitively normal individuals aged 21 to 97 years with known TOMM40 genotype underwent longitudinal neuropsychological testing every 2 years. We estimated the longitudinal effect of age on memory using statistical models that simultaneously modeled cross-sectional and longitudinal effects of age on the Auditory Verbal Learning Test Long-Term Memory score by APOE, TOMM40, and the interaction between the two. RESULTS: There were significant effects overall for both TOMM40 (linear effect, P = .04; quadratic effect, P = .03) and APOE (linear effect, P = .06; quadratic effect, P = .008), with no significant interaction (P = .63). In a piecewise model, there was a significant TOMM40 effect before age 60 years (P = .009), characterized by flattened test-retest improvement (VL/VL subgroup only) but no significant APOE effect, and a significant APOE effect after age 60 years (P = .006), characterized by accelerated memory decline (e4 carriers) but no significant TOMM40 effect. CONCLUSION: Both TOMM40 and APOE significantly influence age-related memory performance, but they appear to do so independently of each other.
BACKGROUND:TOMM40 (translocase of the outer mitochondrial membrane pore subunit) is in linkage disequilibrium with apolipoprotein E (APOE). APOE e4 is linked to long (L; 21-29 T residues) poly-T variants within intron 6 of TOMM40, whereas APOE e3 can be associated with either a short (S; <21 T residues) or very long (VL; >29 T residues) variant. To assess the possible contribution of TOMM40 to Alzheimer's disease onset, we compared the effects of TOMM40 and APOE genotype on preclinical longitudinal memory decline. METHODS: An APOE e4-enriched cohort of 639 cognitively normal individuals aged 21 to 97 years with known TOMM40 genotype underwent longitudinal neuropsychological testing every 2 years. We estimated the longitudinal effect of age on memory using statistical models that simultaneously modeled cross-sectional and longitudinal effects of age on the Auditory Verbal Learning Test Long-Term Memory score by APOE, TOMM40, and the interaction between the two. RESULTS: There were significant effects overall for both TOMM40 (linear effect, P = .04; quadratic effect, P = .03) and APOE (linear effect, P = .06; quadratic effect, P = .008), with no significant interaction (P = .63). In a piecewise model, there was a significant TOMM40 effect before age 60 years (P = .009), characterized by flattened test-retest improvement (VL/VL subgroup only) but no significant APOE effect, and a significant APOE effect after age 60 years (P = .006), characterized by accelerated memory decline (e4 carriers) but no significant TOMM40 effect. CONCLUSION: Both TOMM40 and APOE significantly influence age-related memory performance, but they appear to do so independently of each other.
Authors: Shengjun Chang; Tian ran Ma; R Dennis Miranda; Maureen E Balestra; Robert W Mahley; Yadong Huang Journal: Proc Natl Acad Sci U S A Date: 2005-12-12 Impact factor: 11.205
Authors: Saravanan S Karuppagounder; Hui Xu; Qingli Shi; Lian H Chen; Steve Pedrini; David Pechman; Harriet Baker; M Flint Beal; Sam E Gandy; Gary E Gibson Journal: Neurobiol Aging Date: 2008-04-10 Impact factor: 4.673
Authors: Adam D Humphries; Illo C Streimann; Diana Stojanovski; Amelia J Johnston; Masato Yano; Nicholas J Hoogenraad; Michael T Ryan Journal: J Biol Chem Date: 2005-01-10 Impact factor: 5.157
Authors: Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman Journal: N Engl J Med Date: 2009-07-16 Impact factor: 91.245
Authors: Tracy O'Connor; Katherine R Sadleir; Erika Maus; Rodney A Velliquette; Jie Zhao; Sarah L Cole; William A Eimer; Brian Hitt; Leslie A Bembinster; Sven Lammich; Stefan F Lichtenthaler; Sébastien S Hébert; Bart De Strooper; Christian Haass; David A Bennett; Robert Vassar Journal: Neuron Date: 2008-12-26 Impact factor: 17.173
Authors: Hao Li; Sally Wetten; Li Li; Pamela L St Jean; Ruchi Upmanyu; Linda Surh; David Hosford; Michael R Barnes; James David Briley; Michael Borrie; Natalie Coletta; Richard Delisle; Daniella Dhalla; Margaret G Ehm; Howard H Feldman; Luis Fornazzari; Serge Gauthier; Neil Goodgame; Danilo Guzman; Sandra Hammond; Paul Hollingworth; Ging-Yuek Hsiung; Joan Johnson; Devon D Kelly; Ron Keren; Andrew Kertesz; Karen S King; Simon Lovestone; Inge Loy-English; Paul M Matthews; Michael J Owen; Mary Plumpton; William Pryse-Phillips; Rab K Prinjha; Jill C Richardson; Ann Saunders; Andrew J Slater; Peter H St George-Hyslop; Sandra W Stinnett; Jina E Swartz; Rachel L Taylor; John Wherrett; Julie Williams; David P Yarnall; Rachel A Gibson; Michael C Irizarry; Lefkos T Middleton; Allen D Roses Journal: Arch Neurol Date: 2007-11-12
Authors: Alison C Burggren; Zanjbeel Mahmood; Theresa M Harrison; Prabha Siddarth; Karen J Miller; Gary W Small; David A Merrill; Susan Y Bookheimer Journal: Alzheimers Dement Date: 2017-02-07 Impact factor: 21.566
Authors: Lior Greenbaum; Ramit Ravona Springer; Michael W Lutz; Anthony Heymann; Irit Lubitz; Itzik Cooper; Efrat Kravitz; Mary Sano; Allen D Roses; Jeremy M Silverman; Ann M Saunders; Michal Schnaider Beeri Journal: Eur Neuropsychopharmacol Date: 2014-06-13 Impact factor: 4.600
Authors: Lei Yu; Michael W Lutz; Jose M Farfel; Robert S Wilson; Daniel K Burns; Ann M Saunders; Philip L De Jager; Lisa L Barnes; Julie A Schneider; David A Bennett Journal: Alzheimers Dement Date: 2017-06-15 Impact factor: 21.566
Authors: D G Crenshaw; W K Gottschalk; M W Lutz; I Grossman; A M Saunders; J R Burke; K A Welsh-Bohmer; S K Brannan; D K Burns; A D Roses Journal: Clin Pharmacol Ther Date: 2012-11-07 Impact factor: 6.875